188 related articles for article (PubMed ID: 18664657)
1. Inhibition of tumor growth using salmonella expressing Fas ligand.
Loeffler M; Le'Negrate G; Krajewska M; Reed JC
J Natl Cancer Inst; 2008 Aug; 100(15):1113-6. PubMed ID: 18664657
[TBL] [Abstract][Full Text] [Related]
2. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth.
Loeffler M; Le'Negrate G; Krajewska M; Reed JC
Cancer Immunol Immunother; 2009 May; 58(5):769-75. PubMed ID: 18633610
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment.
Yoon W; Yoo Y; Chae YS; Kee SH; Kim BM
Ann Oncol; 2018 Sep; 29(9):2010-2017. PubMed ID: 30016386
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation by ammonium trichloro(dioxoethylene-0,0') tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101.
Kalechman Y; Strassmann G; Albeck M; Sredni B
J Immunol; 1998 Oct; 161(7):3536-42. PubMed ID: 9759874
[TBL] [Abstract][Full Text] [Related]
6. Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma.
Yoon W; Park YC; Kim J; Chae YS; Byeon JH; Min SH; Park S; Yoo Y; Park YK; Kim BM
Eur J Cancer; 2017 Jan; 70():48-61. PubMed ID: 27883926
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
[TBL] [Abstract][Full Text] [Related]
8. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts.
Springer ML; Kraft PE; Blau HM
Somat Cell Mol Genet; 1998 Sep; 24(5):281-9. PubMed ID: 10696236
[TBL] [Abstract][Full Text] [Related]
10. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs.
Zeytun A; Nagarkatti M; Nagarkatti PS
Blood; 2000 Mar; 95(6):2111-7. PubMed ID: 10706882
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
[TBL] [Abstract][Full Text] [Related]
12. Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation.
Chiu HY; Sun GH; Chen SY; Wang HH; Ho MY; Chu CY; Wu WL; Jhou RS; Tsai YL; Huang RT; Sun KH; Tang SJ
Mol Carcinog; 2013 Sep; 52(9):705-14. PubMed ID: 22488710
[TBL] [Abstract][Full Text] [Related]
13. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
14. Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models.
Liang K; Liu Q; Li P; Han Y; Bian X; Tang Y; Kong Q
Cancer Gene Ther; 2018 Aug; 25(7-8):167-183. PubMed ID: 29755110
[TBL] [Abstract][Full Text] [Related]
15. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
Friedlos F; Lehouritis P; Ogilvie L; Hedley D; Davies L; Bermudes D; King I; Martin J; Marais R; Springer CJ
Clin Cancer Res; 2008 Jul; 14(13):4259-66. PubMed ID: 18594008
[TBL] [Abstract][Full Text] [Related]
16. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
[TBL] [Abstract][Full Text] [Related]
17. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth.
Loeffler M; Le'Negrate G; Krajewska M; Reed JC
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12879-83. PubMed ID: 17652173
[TBL] [Abstract][Full Text] [Related]
18. Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes.
Coe GL; Redd PS; Paschall AV; Lu C; Gu L; Cai H; Albers T; Lebedyeva IO; Liu K
Sci Rep; 2016 Aug; 6():30816. PubMed ID: 27487939
[TBL] [Abstract][Full Text] [Related]
19. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
[TBL] [Abstract][Full Text] [Related]
20. IL-18-producing Salmonella inhibit tumor growth.
Loeffler M; Le'Negrate G; Krajewska M; Reed JC
Cancer Gene Ther; 2008 Dec; 15(12):787-94. PubMed ID: 18654612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
